This clinical trial, which is now actively recruiting for children and adults with a confirmed diagnosis of recessive dystrophic EB (RDEB) or junctional EB (JEB), is focused on testing whether stem cell therapies could help enable the body to close chronic wounds associated with these two types of EB.
The trial is looking for 74 patients with severe forms of EB in various renowned study centers across Europe (EU and UK), Israel, Chile, Argentina, and the US. The study is recruiting and looking for patients (children and adults) with a confirmed diagnosis of recessive dystrophic EB (RDEB) or junctional EB (JEB).
RHEACELL, the commissioning biopharmaceutical company, will cover travel and accommodation expenses for all participants.
If you are interested in participating, please talk to your EB clinician about whether you meet the inclusion criteria and which study site would be suitable for you.